These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 15230945)

  • 1. Safety and supply of haemophilia products: worldwide perspectives.
    Farrugia A
    Haemophilia; 2004 Jul; 10(4):327-33. PubMed ID: 15230945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Product delivery in the developing world: options, opportunities and threats.
    Farrugia A
    Haemophilia; 2004 Oct; 10 Suppl 4():77-82. PubMed ID: 15479376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory challenges to global harmonization and expanded access to concentrates: how will regulators balance the increasing cost of new safety requirements with the desire to increase the availability of affordable product?
    Farrugia A
    Haemophilia; 2004 Oct; 10 Suppl 4():83-7. PubMed ID: 15479377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging and receding risks of therapeutic regimens for haemophilia.
    Farrugia A; Manno CS; Evatt BL
    Haemophilia; 2004 Oct; 10 Suppl 4():47-54. PubMed ID: 15479372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving perspectives in product safety for haemophilia.
    Farrugia A
    Haemophilia; 2002 May; 8(3):236-43. PubMed ID: 12010417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.
    Batlle J; Villar A; Liras A; Alonso C; Altisent C; Brito D; Moreno M; Lucía F; Sedano C; Prieto M; Calvente N; Aznar JA; Jiménez V; Soriano V; Martorell JR; Iruín G; Bergua JM; Aguilar C
    Blood Coagul Fibrinolysis; 2008 Jul; 19(5):333-40. PubMed ID: 18600079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease.
    Josephson CD; Abshire TC
    Best Pract Res Clin Haematol; 2006; 19(1):35-49. PubMed ID: 16377540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Globalisation and blood safety.
    Farrugia A
    Blood Rev; 2009 May; 23(3):123-8. PubMed ID: 19081166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-sufficiency--20 years on.
    Schädlich PK
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S9-14. PubMed ID: 7795147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Legal, financial, and public health consequences of transfusion-transmitted hepatitis C virus in persons with haemophilia.
    Angelotta C; McKoy JM; Fisher MJ; Buffie CG; Barfi K; Ramsey G; Frohlich L; Bennett CL
    Vox Sang; 2007 Aug; 93(2):159-65. PubMed ID: 17683360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasma fractionation in the world: current status].
    Burnouf T
    Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal haemophilia care versus the reality.
    Bolton-Maggs PH
    Br J Haematol; 2006 Mar; 132(6):671-82. PubMed ID: 16487168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The improved factor concentrate.
    Lillicrap D
    Hamostaseologie; 2009 Jan; 29(1):71-3. PubMed ID: 19151851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European principles of haemophilia care.
    Colvin BT; Astermark J; Fischer K; Gringeri A; Lassila R; Schramm W; Thomas A; Ingerslev J;
    Haemophilia; 2008 Mar; 14(2):361-74. PubMed ID: 18248408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing pattern of care of boys with haemophilia in western European centres.
    Chambost H; Ljung R;
    Haemophilia; 2005 Mar; 11(2):92-9. PubMed ID: 15810909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. World Federation of Haemophilia programs in developing countries.
    Giangrande PL; Black C
    Semin Thromb Hemost; 2005 Nov; 31(5):555-60. PubMed ID: 16276464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Products for clotting factor replacement in developing countries.
    Kasper CK
    Semin Thromb Hemost; 2005 Nov; 31(5):507-12. PubMed ID: 16276458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International movement of plasma and plasma contracting.
    Farrugia A
    Dev Biol (Basel); 2005; 120():85-96. PubMed ID: 16050160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.